heavy periods; menstruation was two days early; painful for three days so far instead of the usual one.; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency. regulatory number: gb-mhra-webcovid-202202141027159030-2tfx8 (ra). other case identifier(s): gb-mhra-adr 26600579 (ra). a 34 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 12jan2022 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: bnt162b2 (dose 1, single), for covid-19 immunisation; bnt162b2 (dose 2, single), for covid-19 immunisation. the patient did not have symptoms associated with covid-19. the patient was not pregnant and was not breastfeeding at the time of this report. the patient was not enrolled in clinical trial. last menstrual date of the patient was 11feb2022. patient has not tested positive for covid-19 since having the vaccine. the following information was reported: heavy menstrual bleeding (medically significant) with onset 13feb2022, outcome "recovering", described as "heavy periods"; polymenorrhoea (medically significant) with onset 11feb2022, outcome "recovering", described as "menstruation was two days early"; dysmenorrhoea (medically significant) with onset 2022, outcome "recovered" (2022), described as "painful for three days so far instead of the usual one.". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. this report was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test

na

na